# First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

> **NCT03189719** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 749 (actual)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo
- **DRUG:** Cisplatin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT03189719
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-25
- **Primary completion:** 2020-07-02
- **Final completion:** 2023-07-10
- **Target enrollment:** 749 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189719, "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03189719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*